Navigation Links
BioLife Solutions Announces Strategic Partnership with HemaCare

BOTHELL, Wash., June 25, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, and HemaCare Corporation, (OTCPK:HEMA), a leading supplier of blood derived cells and components for research and clinical applications, today announced a strategic relationship wherein HemaCare will market BioLife's HypoThermosol® and CryoStor® biopreservation media products and HemaCare's blood derived cells to the research and clinical communities.


Pete van der Wal, President and CEO of HemaCare, remarked on the extended shelf life and viability of HemaCare's Bioresearch products, specifically, peripheral blood mononuclear cells (PBMNC's), through the use of BioLife's HypoThermosol storage and shipping medium, "The current gold standard of shipping frozen PBMNC's to researchers requires back-end thawing and culturing before the cells are ready for use.  HypoThermosol has demonstrated remarkable ability to extend the shelf life of this valuable cell type out to 4 days, eliminating the cryopreservation process and its related yield loss, and enabling a worldwide delivery footprint for fresh apheresis-derived cells."

Information on the use of HypoThermosol with HemaCare's apheresis derived cells can be found here: HemaCare data.

Mike Rice, BioLife Solutions President and CEO, commented on the announcement by stating, "HemaCare offers best-in-class bioresearch products derived from the most robust and highest quality apheresis collections.  We're glad to partner with them to enable a new product option for their customers.  We look forward to additional collaborative research that we believe will generate even more data supporting the value proposition of our proprietary biopreservation media products."

More information can be found here:

About HemaCare HemaCare Corporation is a blood services company serving healthcare providers and the scientific community for over 35 years. HemaCare and its subsidiary, Coral Blood Services, perform therapeutic apheresis services, provide human-derived biological products, and support the use of cellular therapies with apheresis collections. The Company was founded in 1978 and is based in Van Nuys, California. The Company assists the scientific community by providing researchers with the human primary cells, blood components, and tissue they need to advance research.  All cellular products and blood components are collected from IRB consented normal donors and patients derived from the following tissues including peripheral blood, mobilized, peripheral blood, bone marrow, and umbilical cord blood.  For more information please visit

About BioLife SolutionsBioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions for cells, tissues, and organs.  The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death.  BioLife's enabling technology provides academic and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs.  For more information please visit, and follow BioLife on Twitter.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact.  Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission.  BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.  Media Relations:Investor Relations:Len Hall

Matt ClawsonAllen & Caron Inc

Allen & Caron Inc(949) 474-4300


SOURCE BioLife Solutions, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer
2. BioLife Solutions 2011 Revenue Up 33%
3. BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board
4. Improved Cord Blood Processing Research on BioLife Solutions CryoStor® Published in TRANSFUSION
5. BioLife Solutions Completes Corporate Facilities Expansion, Build-Out of Additional cGMP Clean Room Manufacturing Suite
6. BioLife Solutions Announces 2012 Second Quarter Results: Eighth Straight Quarter of Record Revenue
7. BioLife Solutions Announces Presentation at IBC Inaugural Cell Therapy Clinical Development Conference
8. BioLife Solutions Announces 2012 Third Quarter Results: Ninth Straight Quarter of Record Revenue
9. BioLife Solutions Announces License Agreement
10. BioLife Solutions Announces Record Revenue of $2.2 Million in First Quarter of 2013
11. BioLife Solutions Named One of Washingtons Best Companies
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... InSphero AG , ... 3D cell culture models, has launched a 14 Day Hepatotoxicity Testing Service ... InSightâ„¢ Human Liver Microtissues. The service streamlines toxicity testing of compounds in ...
(Date:10/13/2015)... 2015 ARRY ), Avanex Life ... JUNO ), and Progenix Pharmaceuticals, Inc. (NASDAQ: PGNX ... Corp. (OTCQX: AVXLD), Juno Therapeutics, Inc. (NASDAQ: JUNO ... --> Cooperative research and development efforts with ... lead to advancements in the treatment of severe wounds. ...
(Date:10/13/2015)... , Oct. 13, 2015  According to ... services will reach $102 billion by the end ... of the health industry, as it is estimated ... result of laboratory tests. In addition to diagnosing ... to evaluate disease progression, monitor drug treatment and ...
(Date:10/13/2015)... ... October 13, 2015 , ... Proove Biosciences, a ... their partnership with the Keck Medicine of the University of Southern California ... T.R.O.J.A.N. Study (Therapeutic Evaluation to Research Clinical Objectives Linking Genotypic and Phenotypic Association ...
Breaking Biology Technology:
(Date:10/6/2015)... Calif. , Oct. 6, 2015  Maverix ... today announced enhancements to its software portfolio with ... analysis kit for differential expression in eukaryotes. The ... which is a cloud-based genomic analysis solution that ... scientific discovery from next-generation sequencing efforts. ...
(Date:10/2/2015)... -- ) has announced ... Using Biometrics" report to their offering. ... of the "Enforcing the Law Using Biometrics" ... Research and Markets ( ) has announced ... Using Biometrics" report to their offering. ...
(Date:9/30/2015)... -- With nearly 300,000 Americans living with spinal cord injuries ... reach 12,500 annually, the role of Independent Living Centers ... Living (SCRS-IL) is increasingly important. SCRS-IL is one ... opening doors to independence for individuals with SCIs by ... technology services and education. "In serving people ...
Breaking Biology News(10 mins):